CHICAGO, July 16, 2025 /PRNewswire/ -- Amphix Bio, a pre-clinical stage company developing a new therapeutic modality for regenerative medicine, received an Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for its lead candidate AMFX-200 for treatment of acute...
Hence then, the article about amphix bio receives fda orphan drug designation for neural regeneration therapeutic to treat acute spinal cord injury was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Amphix Bio receives FDA Orphan Drug Designation for neural regeneration therapeutic to treat acute spinal cord injury )
Also on site :
- Lauren Chapin, the Youngest Kid on ‘Father Knows Best,’ Dies at 80
- Wynn Resorts faces second lawsuit after data breach incident involving employees
- Nancy Guthrie Update: Mexican Mothers Face Hurdles Joining Search